InterVenn Biosciences Announces Clinical Validation of World’s First Glycoproteomic Diagnostic Test

Share on twitter Share on linkedin SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences today announced it has completed clinical and analytical validation in compliance with standards set by the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) of GLORITM, a liquid-biopsy diagnostic test capable of differentiating between malignant and benign female pelvic […]